{
  "schema_version": 1,
  "publication": "cros",
  "scope": "Added source-linked answers from this review; vendor statements are not independent tests.",
  "records": [
    {
      "id": "ve-iqvia-therapies",
      "entity_id": "iqvia",
      "field": "therapeutic_area_evidence",
      "statement": "IQVIA’s FAQ names allergy/respiratory, biosimilars, cardiovascular, cell/gene therapy, CNS, dermatology, endocrinology, GI/hepatology, infection/vaccines, nephrology, obesity, oncology/hematology, ophthalmology, pediatrics, rare disease, reproductive health and rheumatology.",
      "conditions": "This is a company-wide list of marketed expertise. It supplies no indication-specific trial count, proposed team or recruitment result.",
      "evidence_role": "vendor_claim",
      "source_url": "https://www.iqvia.com/solutions/therapeutics",
      "retrieved_at": "2026-11-14T03:56:44.432492+00:00",
      "source_snapshot_sha256": "62f9cd25b56159fef22b58b8cab99a98e7be9feca4eb062a4c1112a876a60aac",
      "source_locator": "FAQ L643–L645",
      "publisher": "IQVIA"
    },
    {
      "id": "ve-icon-phase",
      "entity_id": "icon",
      "field": "phase_evidence",
      "statement": "ICON’s Clinical and Scientific Operations page explicitly covers planning, managing, running and analysing Phase 2–3 trials.",
      "conditions": "This general clinical-operations claim is broader than its separate Accellacare in-home page. It is not proof of success in your protocol.",
      "evidence_role": "vendor_claim",
      "source_url": "https://www.iconplc.com/solutions/clinical-scientific-operations",
      "retrieved_at": "2026-11-14T03:56:44.426308+00:00",
      "source_snapshot_sha256": "c0aaad4b280ab5515db09d6167ce8ea1e29a85736cac7f594be5341d171b796b",
      "source_locator": "L1–L3",
      "publisher": "ICON"
    },
    {
      "id": "ve-icon-therapies",
      "entity_id": "icon",
      "field": "therapeutic_area_evidence",
      "statement": "ICON names cardio-metabolic, oncology/hematology, infectious disease, neurology/psychiatry, rare disease, respiratory and biosimilars.",
      "conditions": "Company-wide therapeutic expertise; confirm the exact indication and proposed staff’s experience.",
      "evidence_role": "vendor_claim",
      "source_url": "https://www.iconplc.com/solutions/clinical-scientific-operations",
      "retrieved_at": "2026-11-14T03:56:44.426308+00:00",
      "source_snapshot_sha256": "c0aaad4b280ab5515db09d6167ce8ea1e29a85736cac7f594be5341d171b796b",
      "source_locator": "L37–L40",
      "publisher": "ICON"
    },
    {
      "id": "ve-icon-model",
      "entity_id": "icon",
      "field": "service_scope",
      "statement": "ICON describes traditional, decentralized and hybrid trial models on its clinical-operations page.",
      "conditions": "These describe visit/delivery models, not evidence that all functions are included in one quoted contract.",
      "evidence_role": "vendor_claim",
      "source_url": "https://www.iconplc.com/solutions/clinical-scientific-operations",
      "retrieved_at": "2026-11-14T03:56:44.426308+00:00",
      "source_snapshot_sha256": "c0aaad4b280ab5515db09d6167ce8ea1e29a85736cac7f594be5341d171b796b",
      "source_locator": "L37–L40",
      "publisher": "ICON"
    },
    {
      "id": "ve-medpace-therapies",
      "entity_id": "medpace",
      "field": "therapeutic_area_evidence",
      "statement": "Medpace’s FAQ covers cardiovascular, dermatology, endocrine/metabolic, GI/hepatology, immunology/inflammation, infection/vaccines, nephrology, neuroscience, oncology/hematology, ophthalmology, respiratory and rheumatology. It also names rare disease, pediatrics, cell/gene therapy and other crossovers.",
      "conditions": "The FAQ describes Phase I–IV support. This is not a count of recent trials, US sites or staff available for a specific indication.",
      "evidence_role": "vendor_claim",
      "source_url": "https://www.medpace.com/about/",
      "retrieved_at": "2026-11-14T03:56:44.432492+00:00",
      "source_snapshot_sha256": "648e644e0357c50d0d35f6a7601a7c83178d504373d5b6877ac610e9859b1316",
      "source_locator": "FAQ L202–L229",
      "publisher": "Medpace"
    },
    {
      "id": "ve-medpace-team",
      "entity_id": "medpace",
      "field": "team_continuity_claim",
      "statement": "Medpace says one team stays with a project from early discussions through completion.",
      "conditions": "This is a vendor promise, not a named-team commitment or measured retention result. Ask the proposal to name roles, allocation and substitution terms.",
      "evidence_role": "vendor_claim",
      "source_url": "https://www.medpace.com/about/",
      "retrieved_at": "2026-11-14T03:56:44.432492+00:00",
      "source_snapshot_sha256": "648e644e0357c50d0d35f6a7601a7c83178d504373d5b6877ac610e9859b1316",
      "source_locator": "L234–L236",
      "publisher": "Medpace"
    }
  ]
}
